AllSci News
Beam reports durable BEAM-302 AAT restoration, advances pivotal cohort
Updated Phase I/II data from Beam Therapeutics' (Nasdaq: BEAM) BEAM-302 program, presented at the European Respiratory Society Congress in Barcelona, show...
Korsana goes public with USD 380m raise and Alzheimer's antibody poised for Phase I
Waltham, Massachusetts-based Korsana Biosciences (Nasdaq: KRSA) has completed its reverse merger with Cyclerion Therapeutics and closed a USD 380 million...
Evommune's EVO756 suffers second Phase IIb setback in two months with AD miss
California-based Evommune, Inc. (NYSE: EVMN) revealed EVO756, an oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist, failed to meet its...
Insilico's IPF drug rentosertib shows biological age reversal in exploratory proteomic analysis
A new analysis published in Nature Biotechnology adds an unexpected dimension to the clinical profile of rentosertib, the AI-designed TNIK inhibitor from...
Semaglutide clears obesity treatment threshold in children aged 6 to under 12
Phase III data from Novo Nordisk's STEP Young trial show that once-weekly semaglutide (Wegovy, Ozempic, Rybelsus) reduced body mass index (BMI) in children...
Sernova, Seraxis merge to build integrated stem cell islet replacement platform for T1D
Canada-based Sernova Biotherapeutics Inc. (TSX: SVA) and Germantown, Maryland-based Seraxis Holdings, Inc. have signed a definitive merger agreement to...
Cloverleaf Bio lands USD 33m seed with Lilly, AbbVie, and Boehringer backing
Connecticut-based Cloverleaf Bio has raised USD 33 million in an oversubscribed seed financing round to advance a platform of engineered transfer RNA...
AirNexis’s AN01 improves lung function on top of bronchodilators in COPD
A dual phosphodiesterase inhibitor delivered by dry powder inhaler met its primary endpoint in a Phase IIb randomized trial in chronic obstructive pulmonary...
Windward’s TSLP mAb shows six-month asthma activity after single dose
Positive Phase II interim data from SKB378/WIN378, an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody engineered for extended half-life, have...
Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date
Cambridge, Massachusetts-based Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced that the US FDA has accepted its Biologics License Application (BLA) and...
BMS’s GPRC5D CAR-T clears registrational trial in quadruple-exposed multiple myeloma
Arlocabtagene autoleucel met the primary endpoint of overall response rate (ORR) and all key secondary endpoints in the registrational QUINTESSENTIAL Phase...
Inhibrx's OX40 agonist nearly doubles response rate versus Keytruda alone in head and neck cancer
A hexavalent OX40 agonist that has struggled to find clinical traction across the broader class has now produced the first randomized efficacy signal for an...
German researchers show AI-designed protein vehicles outperform lipid nanoparticles in RNA delivery
Researchers at Helmholtz Munich and the Technical University of Munich, led by corresponding authors Christoph Gruber, Florian Giesert, and Wolfgang Wurst,...
Novo Nordisk scraps two Phase III ziltivekimab trials after ZEUS failure
Two large Phase III trials of ziltivekimab, Novo Nordisk's investigational IL-6 inhibitor, have been stopped early on the recommendation of an independent...
PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC
New Jersey-based PDS Biotechnology Corporation (Nasdaq: PDSB) has raised up to USD 22.55 million in a private investment in public equity (PIPE) transaction...
The AllSci Brief
Free, systematic R&D and deal news. Daily.